SCHEMBL14725941

SCHEMBL14725941

O=Cc1nc2c(N3CCOCC3)nc(Br)cn2n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GAA P10253 1/20 0.36
POLB P06746 2/20 0.36
MAPK1 P28482 1/20 0.35
TSHR P16473 1/20 0.35
HTR2C P28335 1/20 0.34
PIK3CA P42336 4/20 0.33
PIK3R1 P27986 3/20 0.33
PIK3CD O00329 2/20 0.33
PIK3CB P42338 2/20 0.33
MTOR P42345 2/20 0.33
PIK3CG P48736 2/20 0.33
ABL1 P00519 1/20 0.32
BCR P11274 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
AR P10275 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12463000 0.84 ALDH1A1 (0.37) ALDH1A1L3MBTL1GAAPOLBPIK3CA
SCHEMBL14725935 0.79 ALDH1A1 (0.39) ALDH1A1POLBMAPK1TSHRPIK3CA
SCHEMBL26071904 0.77 KDM4E (0.39) ALDH1A1L3MBTL1POLBMAPK1PIK3CA
SCHEMBL5561919 0.76 HTR2C (0.39) ALDH1A1L3MBTL1GAAPOLBMAPK1
SCHEMBL14725940 0.76 PIK3CA (0.39) ALDH1A1POLBMAPK1TSHRHTR2C
SCHEMBL14725934 0.76 PIK3R1 (0.39) ALDH1A1GAAPOLBMAPK1TSHR
SCHEMBL14725937 0.75 PDE4A (0.36) ALDH1A1GAAPOLBMAPK1TSHR
SCHEMBL14725943 0.74 POLB (0.34) ALDH1A1POLBMAPK1TSHRHTR2C
SCHEMBL14725938 0.73 PIK3CA (0.47) ALDH1A1GAAPOLBMAPK1TSHR
SCHEMBL26072504 0.71 ALOX15 (0.45) ALDH1A1L3MBTL1GAAPOLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2526102-B1 Inhibitors of PI3 kinase FUNDACIÓN CENTRO NAC DE INVESTIG ONCOLÓGICAS CARLOS III (ES) 2017-03-08 EP disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053371-A1 INHIBITORS OF PI3 KINASE PIK3CA, MTOR, PIK3C2A ALDH1A1 2425/4885L3MBTL1 594/4885GAA 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.